Effect of estimated prostate volume on silodosin-mediated improvements in the signs and symptoms of BPH: does prostate size matter?

Steven A Kaplan1, Claus G Roehrborn2, Lawrence A Hill3, Weining Volinn31Weill College of Medicine Cornell University, New York, NY, USA; 2University of Texas Southwestern Medical Center, Dallas, TX, USA; 3Watson Laboratories Inc., Salt Lake City, UT, USAObjective: The uroselective α-blocker silodosin significantly improved International Prostate Symptom Score (IPSS) in two 12-week, double-blind (DB), placebo-controlled Phase III studies in men aged ≥ 50 years with symptoms of benign prostatic hyperplasia (BPH) and maintained symptom improvement during a 9-month open-label (OL) extension. This post-hoc analysis evaluated the effects of estimated prostate volume (EPV) on silodosin-mediated symptom improvement.Methods: Patients were stratified by EPV (